Glipizide
Rank #264 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$46.9M
Total Cost
2,961,035
Total Claims
$46.9M
Total Cost
80,655
Prescribers
$16
Cost per Claim
564,206
Beneficiaries
7,065,415
30-Day Fills
$581
Avg Cost/Provider
37
Avg Claims/Provider
Share of Medicare Part D Spending
0.02%
of total Medicare Part D spending
$46.9M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $46.9M total
🔎 Data Overview
At $16.00 per prescription, this is an affordable generic medication. Wider use of affordable generics like this could save Medicare billions annually.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Glipizide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Chee-Yeung Chan | Endocrinology | Mount Kisco, NY | 595 | $22K |
| 2 | Michael Correa | Internal Medicine | New York, NY | 646 | $20K |
| 3 | Alberto Romero | Family Practice | Pasadena, TX | 416 | $19K |
| 4 | Carlos Martinez Rivera | Endocrinology | Mayaguez, PR | 1,060 | $17K |
| 5 | Jose Escandon | Internal Medicine | Mission, TX | 633 | $17K |
| 6 | Maritza Melendez Nieves | Internal Medicine | Fajardo, PR | 232 | $16K |
| 7 | Dayal Raja | Endocrinology | New Hartford, NY | 802 | $15K |
| 8 | Minping Liu | Internal Medicine | Boston, MA | 292 | $15K |
| 9 | Patricia Grindell | Nurse Practitioner | Fall River, MA | 460 | $14K |
| 10 | Michael Lin | Endocrinology | San Gabriel, CA | 339 | $14K |
| 11 | Philip Nicol | Internal Medicine | Murrells Inlet, SC | 433 | $14K |
| 12 | Nahrain Alzubaidi | Endocrinology | Falls Church, VA | 343 | $14K |
| 13 | Shant Parseghian | Endocrinology | Stoneham, MA | 419 | $13K |
| 14 | David Castellone | Family Practice | Summerville, SC | 450 | $13K |
| 15 | Ajay Meka | Internal Medicine | Santa Ana, CA | 679 | $13K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 261 | Cenobamate (Xcopri) | $47.6M | 33,831 |
| 262 | Clozapine (Clozapine) | $47.0M | 491,951 |
| 263 | Pembrolizumab (Keytruda) | $46.9M | 3,947 |
| 264 | Glipizide (Glipizide) | $46.9M | 2,961,035 |
| 265 | Losartan/Hydrochlorothiazide (Losartan-Hydrochlorothiazide) | $46.3M | 2,039,676 |
| 266 | Darunavir (Prezista) | $46.0M | 21,793 |
| 267 | C1 Esterase Inhibitor (Haegarda) | $45.8M | 894 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology